comparemela.com

Latest Breaking News On - Cadila health - Page 4 : comparemela.com

Zydus Cadila s Virafin gets emergency use approval for treating moderate COVID-19 cases

(PTI Photo) New Delhi: Zydus Cadila has received emergency use approval from the Drugs Controller General of India (DGCI) for the use of Virafin in treating moderate Covid-19 infection in adults. A single-dose of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID-19, Virafin will help patients recover faster and avoid much of the complications, the company said. In a release, Cadila Health highlighted that the drug has also shown efficacy against other viral infections. Speaking on the development, Dr Sharvil Patel, Managing Director, Cadila Healthcare Limited, said, The fact that we are able to offer a therapy which significantly reduces the viral load when given early on can help in better disease management. It comes at a much-needed time for patients and we will continue to provide them access to critical therapies in this battle against COVID-19.

Here s why investors lost Rs 7 trillion in trade on Monday

Read more about Here s why investors lost Rs 8 trillion in trade on Monday on Business Standard. Index heavyweights such as Reliance Industries, HDFC Bank, HDFC, ICICI Bank, SBI, Bajaj Finance, TCS, and L&T declined up to 7 per cent.

Market Movers: Dr Reddy s, Cadila Health surge; 112 stocks blink buy

Market Movers: Dr Reddy’s, Cadila Health surge; 112 stocks blink buy SECTIONS Share Synopsis Despite weakness in headline indices, as many as 112 stocks listed on the NSE gave buy signals based on MACD indicators. The list included PNB, JSW Energy, Zee Entertainment Enterprises, and Kotak Mahindra Bank. Shutterstock.com For the day, the Nifty50 index ended 0.3 per cent, or 39 points, lower at 14,834.9, while the BSE-Sensex closed at 49,591.32, down 155 points or 0.3 per cent. Related MUMBAI: Benchmark equity indices had a tepid day today as investors remained concerned over the impact of sharp rise in COVID-19 infections on the country’s economic recovery and corporate earnings.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.